GlassScriptPhysician profile
Johnna J Bridges
NPI 1114007424
$3,988.42
in general payments reported to CMS, 2019-2025
30 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $1,674 · 2023: $1,454 · 2024: $363 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552 · Education: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.51 |
| Education | $410.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,036.63 | 2022-2023 | Urolift |
| Dendreon Pharmaceuticals LLC | $367.10 | 2022-2023 | Provenge |
| Astellas Pharma US INC | $366.66 | 2022-2024 | Myrbetriq, Veozah, Xtandi |
| Endo Pharmaceuticals INC. | $289.79 | 2022-2024 | Xiaflex, Aveed, Edex |
| Antares Pharma, INC. | $250.08 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Janssen Biotech, INC. | $242.94 | 2022-2025 | Tremfya |
| Myriad Genetic Laboratories, INC. | $215.79 | 2022-2024 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $168.13 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $155.96 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $136.09 | 2023-2024 | Orgovyx, Gemtesa |
| Pfizer INC. | $131.43 | 2023-2024 | |
| Halozyme INC | $71.29 | 2023 | |
| Lilly USA, LLC | $61.55 | 2021 | |
| Sun Pharmaceutical Industries INC. | $58.91 | 2022 | |
| Dexcom, INC. | $51.97 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $48.19 | 2023-2024 | |
| Boston Scientific Corporation | $43.09 | 2022-2025 | Spaceoar Vue System - 10ml |
| Takeda Pharmaceuticals U.S.A., INC. | $41.80 | 2021-2022 | |
| Novo Nordisk INC | $30.44 | 2021 | |
| Abc Home Medical Supply, INC. | $28.88 | 2022 | |
| 180 Medical, INC. | $28.44 | 2024 | Gentlecath |
| Janssen Pharmaceuticals, INC | $26.67 | 2021 | |
| Abbvie INC. | $21.73 | 2024 | |
| Palette Life Sciences, INC. | $20.53 | 2022 | |
| Procept Biorobotics Corporation | $19.11 | 2023 | Aquabeam Robotic System |
| Urovant Sciences INC | $17.95 | 2022 | |
| Amgen INC. | $16.57 | 2024 | Otezla |
| Telix Pharmaceuticals | $14.29 | 2023 | Illuccix |
| Axonics, INC. | $13.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnna Bridges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.